CDYL: A Promising Drug Target and Biomarker for Chromodomain-Y-Containing Proteins

Target Name: CDYL

NCBI ID: G9425

CDYL

CDYL: A Promising Drug Target and Biomarker for Chromodomain-Y-Containing Proteins

CDYL (Chromodomain-Y-Containing) proteins are a diverse family of proteins that play crucial roles in various cellular processes. These proteins are involved in various cellular processes, including DNA replication, transcription, and repair. CDYL proteins have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. As a result, targeting CDYL proteins has become an attractive research topic in recent years.

CDYL Proteins and Their Functions

CDYL proteins are a subfamily of the Chromodomain-Y (CDY) protein family. The CDY protein family is characterized by the presence of a specific domain, known as the CDY domain, which is responsible for the protein's unique structure and function. The CDY domain is a conserved region that is responsible for the protein's stability and stability-dependent interactions with other proteins.

CDYL proteins are involved in various cellular processes, including DNA replication, transcription, and repair. They are also involved in the regulation of cell growth, apoptosis, and autophagy. CDYL proteins have also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

CDYL as a Drug Target

CDYL proteins have emerged as a promising drug target due to their involvement in various cellular processes that are associated with the development and progression of diseases. One of the main advantages of targeting CDYL proteins is their ability to interact with a wide range of proteins, making them an attractive target for small molecules.

CDYL has been shown to play a role in various cellular processes, including the regulation of cell growth, apoptosis, and autophagy. Therefore, small molecules that can modulate these processes have the potential to be effective against CDYL-related diseases.

CDYL as a Biomarker

CDYL proteins have also been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and autophagy. Therefore, measuring the levels of CDYL proteins in tissues or fluids can be an effective way to diagnose and monitor the progression of diseases associated with CDYL mutations.

CDYL has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, measuring the levels of CDYL proteins in tissues or fluids can be an effective way to diagnose and monitor the progression of these diseases.

Conclusion

In conclusion, CDYL proteins are a diverse family of proteins that play crucial roles in various cellular processes. Their involvement in the development and progression of various diseases makes them an attractive target for small molecules. Furthermore, CDYL proteins have also been shown to be involved in the regulation of cellular processes that are associated with the development and progression of diseases. Therefore, measuring the levels of CDYL proteins in tissues or fluids can be an effective way to diagnose and monitor the progression of these diseases. Further research is needed to fully understand the role of CDYL proteins in diseases and to develop effective treatments.

Protein Name: Chromodomain Y Like

Functions: Chromatin reader protein that recognizes and binds histone H3 trimethylated at 'Lys-9', dimethylated at 'Lys-27' and trimethylated at 'Lys-27' (H3K9me3, H3K27me2 and H3K27me3, respectively) (PubMed:19808672, PubMed:28402439). Part of multimeric repressive chromatin complexes, where it is required for transmission and restoration of repressive histone marks, thereby preserving the epigenetic landscape (PubMed:28402439). Required for chromatin targeting and maximal enzymatic activity of Polycomb repressive complex 2 (PRC2); acts as a positive regulator of PRC2 activity by bridging the pre-existing histone H3K27me3 and newly recruited PRC2 on neighboring nucleosomes (PubMed:22009739). Acts as a corepressor for REST by facilitating histone-lysine N-methyltransferase EHMT2 recruitment and H3K9 dimethylation at REST target genes for repression (PubMed:19061646). Involved in X chromosome inactivation in females: recruited to Xist RNA-coated X chromosome and facilitates propagation of H3K9me2 by anchoring EHMT2 (By similarity). Promotes EZH2 accumulation and H3K27me3 methylation at DNA double strand breaks (DSBs), thereby facilitating transcriptional repression at sites of DNA damage and homology-directed repair of DSBs (PubMed:29177481). Required for neuronal migration during brain development by repressing expression of RHOA (By similarity). By repressing the expression of SCN8A, contributes to the inhibition of intrinsic neuronal excitability and epileptogenesis (By similarity). In addition to acting as a chromatin reader, acts as a hydro-lyase (PubMed:28803779). Shows crotonyl-coA hydratase activity by mediating the conversion of crotonyl-CoA ((2E)-butenoyl-CoA) to beta-hydroxybutyryl-CoA (3-hydroxybutanoyl-CoA), thereby acting as a negative regulator of histone crotonylation (PubMed:28803779). Histone crotonylation is required during spermatogenesis; down-regulation of histone crotonylation by CDYL regulates the reactivation of sex chromosome-linked genes in round spermatids and histone replacement in elongating spermatids (By similarity). By regulating histone crotonylation and trimethylation of H3K27, may be involved in stress-induced depression-like behaviors, possibly by regulating VGF expression (By similarity)

The "CDYL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDYL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets